Alex Fair of Medstartr has alerted us to Bayer’s G4A Partnerships for their accelerator to develop and scale breakthrough solutions anchored in behavioral science. The program now covers 35 countries to collaborate with startups and healthcare technology companies that are developing innovative solutions in health and care.
Health areas include Cardiovascular, Digital Therapeutics, Global Health, Oncology, Ophthalmology, Pulmonology, Radiology and Women’s Health.
G4A has two tracks for companies based on development stage:
Growth Track: for companies in the pre-product launch stage. Ideal candidates are seed-stage startups with a Minimal Viable Product validated through acquisition of patents and in publications. Funding is €50-100K to partner + co-create products and solutions with Bayer, plus co-working space in Berlin.
Advance Track: a mature company with a product in the market. Companies will be working jointly with Bayer experts to drive a commercial partnership, co-funded by G4A. There’s a €50-100K initial investment followed by incremental milestone-based payments.
Since 2013, G4A has supported over 150 digital health companies, resulting in 30 direct collaborations, the most recent award being in January: KinAptic (US), Agamon (Israel/UK), and Cyclica (Canada). To apply, see the Partnership page and click on Apply Now. Finalists will be notified in August for the formal announcement in Berlin in early October. But you have to move quickly. as it closes 31 May!